

# Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/L0D6A5A8472EN.html>

Date: December 2019

Pages: 98

Price: US\$ 2,000.00 (Single User License)

ID: L0D6A5A8472EN

## Abstracts

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.

Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 5, 1, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Liver Failure (Hepatic Insufficiency) - Overview

Liver Failure (Hepatic Insufficiency) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development

Celgene Corp

EA Pharma Co Ltd

Genentech Inc

Grifols SA

HepaRegeniX GmbH

Hepatx Corp

Immune Pharmaceuticals Inc

Mallinckrodt Plc

Martin Pharmaceuticals Inc

Mina Therapeutics Ltd

Mylan NV

PledPharma AB

Promethera Biosciences SA

Proterris Inc

RHEACELL GmbH & Co KG

Steminent Biotherapeutics Inc

Takeda Pharmaceutical Co Ltd

Tianjin Weikai Bioeng Ltd

Unicyte AG

Liver Failure (Hepatic Insufficiency) - Drug Profiles

albumin (human) - Drug Profile

Product Description

Mechanism Of Action  
R&D Progress  
Cell Therapy for Liver Failure - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
E-3112 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
enasidenib mesylate - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
F-573 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
HepaStem - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
ipatasertib - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
MTL-CEBPA - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
ornithine phenylacetate - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
PP-100 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
resatorvid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silibinin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Acute Liver Failure, Delayed Graft Function, Non-Alcoholic

Steatohepatitis and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Liver Failure, Type 1 Diabetes and Urea Cycle Disorders -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Diabetic Foot Ulcers, Epidermolysis Bullosa, Liver Diseases,

Kidney Disease, Peripheral Artery Occlusive Disease and Skin Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stemchymal - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trimetazidine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Liver Failure (Hepatic Insufficiency) - Dormant Projects

Liver Failure (Hepatic Insufficiency) - Discontinued Products

Liver Failure (Hepatic Insufficiency) - Product Development Milestones

Featured News & Press Releases

Nov 11, 2019: Promethera Biosciences presents updated clinical results at AASLD 2019 for world's first stem cell therapy trial using HepaStem in acute-on-chronic liver failure

May 09, 2019: Promethera Biosciences announces first-dosing in phase 2a clinical study evaluating world's first liver stem cell therapy in late-stage NASH patients

Apr 15, 2019: Promethera Biosciences presents updated Phase 2a results for world's first stem cell clinical trial in ACLF at The International Liver Congress/ EASL 2019

Mar 27, 2019: Promethera Biosciences announces late-breaking data presentation at EASL 2019 from World First Liver Stem Cell Clinical Trial in ACLF

Mar 12, 2019: Promethera Biosciences to attend and present at upcoming scientific and partnering conferences in March and April

Aug 29, 2018: cGMP Compliance Status for Promethera Biosciences' Production Site in Durham, NC Confirmed by Health Canada

Mar 29, 2018: Martin Pharmaceuticals Receives FDA Orphan Drug Designation for LIVANTRA

Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016

Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure

Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases

Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases

Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation



[Contact Us](#)  
[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Celgene Corp, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by EA Pharma Co Ltd, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Genentech Inc, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Grifols SA, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by HepaRegeniX GmbH, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Hepatx Corp, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Mallinckrodt Plc, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Martin Pharmaceuticals Inc, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Proterris Inc, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by RHEACELL GmbH & Co KG, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Steminent Biotherapeutics Inc, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Tianjin Weikai Bioeng Ltd, H2 2019

Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H2 2019

Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2019

Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2019 (Contd..1), H2 2019

Liver Failure (Hepatic Insufficiency) - Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Celgene Corp  
EA Pharma Co Ltd  
Genentech Inc  
Grifols SA  
HepaRegeniX GmbH  
Hepatx Corp  
Immune Pharmaceuticals Inc  
Mallinckrodt Plc  
Martin Pharmaceuticals Inc  
Mina Therapeutics Ltd  
Mylan NV  
PledPharma AB  
Promethera Biosciences SA  
Proterris Inc  
RHEACELL GmbH & Co KG  
Steminent Biotherapeutics Inc  
Takeda Pharmaceutical Co Ltd  
Tianjin Weikai Bioeng Ltd  
Unicyte AG

## I would like to order

Product name: Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/L0D6A5A8472EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L0D6A5A8472EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970